Case 1:13-cv-01461-RGA Document 93 Filed 05/28/14 Page 1 of 2 PageiD #: 1234
`
`"\~. AO 120 (Rev. 3/04)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § I I 16 you are hereby advised that a court action has been
`on the following X Patents or
`
`Trademarks:
`
`filed in the U.S. District Court
`
`Delaware
`
`DOCKET NO.
`13cv1461-RGA
`PLAINTIFF
`
`DATE FILED
`8/20/2013
`
`U.S. DISTRICT COURT
`
`DEFENDANT
`
`DISTRICT OF DELAWARE
`
`Reckitt Benckiser Pharmaceuticals Inc., et al.
`
`Par Pharmaceutical Inc., et al.
`
`PATENTOR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`8,475,832
`
`8,017,150
`
`7/2/2013
`
`9/13/2011
`
`HOLDER OF PATENT OR TRADEMARK
`
`RB Pharmaceuticals Limited
`
`Mo noSol RX LLC
`
`8,603,514
`
`12/10/2013
`
`MonoSol RX LLC
`
`I
`
`2
`
`3
`
`4
`
`5
`
`In the above--entitled case, the following patent(s)/ trademark(s) have been included:
`
`DATE INCLUDED
`
`PATENTOR
`TRADEMARK NO.
`
`INCLUDED BY
`
`0 Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`0 Answer
`
`0 CrossBill
`
`0 Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`I
`
`2
`
`3
`
`4
`
`5
`
`In the above--entitled case, the following decision has been rendered or judgement issued:
`
`DECISION/JUDGEMENT
`
`See attached Order
`
`CLERK
`
`(BY) DEPUTY CLERK
`
`JOHN A. CERINO, CLERK OF COURT
`
`DATE
`
`5/28/2014
`
`Copy 1-Upon initiation of action, mail this copy to Director Copy 3-Upon termination of action, mail this copy to Director
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Case 1:13-cv-02003-RGA Document 62 Filed 05/09/14 Page 1 of 2 PageiD #: 738
`
`<\lb AO 120 (Rev. 3/04)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`X Patents or
`
`filed in the U.S. District Court ____ ---"D~e""la::.:w'"'a"'re:::.._ ____ on the following
`
`Trademarks:
`
`DOCKET NO.
`13cv2003-RGA
`PLAINTIFF
`
`DATE FILED
`12/6/2013
`
`U.S. DISTRICT COURT
`
`DEFENDANT
`
`DISTRICT OF DELAWARE
`
`Reckitt Benckiser Pharmaceuticals Inc., et a!.
`
`Alvogen Pine Brook Inc., eta!.
`
`PATENTOR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`8,475,832
`
`8,017,150
`
`7/2/2013
`
`9/13/2011
`
`HOLDER OF PATENT OR TRADEMARK
`
`RB Pharmaceuticals Limited
`
`Mo noSol RX LLC
`
`8,603,514
`
`12/10/2013
`
`MonoSol RX LLC
`
`1
`
`2
`
`3
`
`4
`
`5
`
`In the above--entitled case, the following patent(s)/ trademark(s) have been included:
`
`DATE INCLUDED
`
`INCLUDED BY
`
`PATENTOR
`TRADEMARK NO.
`
`D Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`D Answer
`
`D Cross Bill
`
`D Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`I
`
`2
`
`3
`
`4
`
`5
`
`In the above--entitled case, the following decision has been rendered or judgement issued:
`
`DECISION/JUDGEMENT
`
`See attached Order
`
`CLERK
`
`(BY) DEPUTY CLERK
`
`JOHN A. CERINO, CLERK OF COURT
`
`DATE
`
`5/9/2014
`
`Copy 1-Upon initiation of action, mail this copy to Director Copy 3-Upon termination of action, mail this copy to Director
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Case 1:14-cv-00422-UNA Document 4 Filed 04/04/14 Page 1 of 1 PageiD #: 180
`
`AO 120 (Rev. 08110)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`DELAWARE
`on the following
`filed in the U.S. District Court
`0 Trademarks or
`0 Patents.
`( 0 the patent action involves 35 U.S.C. § 292.):
`
`DOCKET NO.
`
`DATE FILED
`4/4/2014
`
`U.S. DISTRICT COURT
`
`DELAWARE
`
`DEFENDANT
`PLAINTIFF
`PAR PHARMACEUTICAL, INC. and INTELGENX
`RECKITT BENCKISER PHARMACEUTICALS INC., RB
`PHARMACEUTICALS LIMITED, and MONOSOL RX LLC TECHNOLOGIES CORP.
`
`PATENTOR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`1 8,475,832
`
`2 8,017,150
`
`3 8,603,514
`
`4
`
`5
`
`7/2/2013
`
`9/13/2011
`
`RB Pharmaceuticals Limited
`
`MonoSol RX, LLC
`
`12/10/2013
`
`MonoSol RX, LLC
`
`In the above-entitled case, the following patent(s)/ trademark(s) have been included:
`
`DATE INCLUDED
`
`PATENTOR
`TRADEMARK NO.
`
`INCLUDED BY
`
`D Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`0 Answer
`
`0 Cross Bill
`
`0 Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`I
`
`2
`
`3
`
`4
`
`5
`
`I DECISION/JUDGEMENT
`
`In the above-entitled case, the following decision has been rendered or judgement issued:
`
`I (BY) DEPUTY CLERK
`
`Copy 1-Upon initiation of action, mail this copy to Director Copy 3-Upon termination of action, mail this copy to Director
`Copy 2-Upon filing document adding patent(s), mail this copy to Director Copy 4-Case file copy
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Case 1:13-cv-01461-RGA Document 57 Filed 02/18/14 Page 1 of 1 PageiD #: 632
`
`AO 120 (Rev. 08/10}_
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`of Delaware
`on the following
`filed in the U.S. District Court
`~Patents. ( 0 the patent action involves 35 U.S.C. § 292.):
`D Trademarks or
`
`DATE FILED
`8/20/2013
`
`U.S. DISTRICT COURT
`
`DOCKET NO.
`13-cv-1461-RGA
`DEFENDANT
`PLAINTIFF
`PAR PHARMACEUTICAL, INC., INTELGENX
`RECKITT BENCKISER PHARMACEUTICALS, INC., RB
`PHARMACEUTICALS LIMITED and MONOSOL RX, LLC, TECHNOLOGIES CORP., and L TS LOHMANN THERAPY
`SYSTEMS CORP.
`
`of Delaware
`
`PATENTOR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`l U.S. 8,475,832
`
`2 U.S. 8,017,150
`
`7/2/2013
`
`9/13/2011
`
`RB Pharmaceuticals Limited
`
`MonoSol Rx, LLC
`
`3
`
`4
`
`5
`
`DATE IN2JWJ2n~ 4
`
`PATENTOR
`TRADEMARK NO.
`I u.s. 8,603,514
`
`In the above-entitled case, the following patent(s)/ trademark(s) have been included:
`
`INCLUDED BY
`
`~Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`0 Answer
`
`0 Cross Bill
`
`0 Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`12/10/2013
`
`MonoSol RX, LLC
`
`2
`
`3
`
`4
`
`5
`
`In the above-entitled case, the following decision has been rendered or judgement issued:
`
`IDECISIONIJUDGEMEN r
`
`I (RY) DEPUTY CLERK
`
`Copy 1-Upon initiation of action, mail this copy to Director Copy 3-Upon termination of action, mail this copy to Director
`Copy 2-Upon filing document adding patent(s), mail this copy to Director Copy 4---Case file copy
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Case 1:13-cv-01674-RGA Document44 Filed 02/18/14 Page 1 of 1 PageiD #: 603
`
`AO 120 (Rev. 08110)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U .S.C. § 290 and/or I 5 U.S.C. § ll I 6 you are hereby advised that a court action has been
`of Delaware
`on the following
`filed in the U.S. District Court
`D Trademarks or
`~Patents. ( D the patent action involves 35 U.S.C. § 292.):
`
`DOCKET NO.
`13-cv-167 4-RGA
`DEFENDANT
`PLAINTIFF
`RECKITT BENCKISER PHARMACEUTICALS, INC., RB WATSON LABORATORIES, INC.
`PHARMACEUTICALS LIMITED and MONOSOL RX, LLC,
`
`of Delaware
`
`DATE FILED
`10/8/2013
`
`U.S. DISTRICT COURT
`
`PATENTOR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`I U.S. 8,475,832
`
`7/2/2013
`
`RB Pharmaceuticals Limited
`
`2 U.S. 8,017,150
`
`9/13/2011
`
`MonoSol Rx, LLC
`
`3
`
`4
`
`5
`
`In the above-entitled case, the following patent(s)/ trademark(s) have been included:
`
`DATE~7WBm4
`
`PATENTOR
`TRADEMARK NO.
`
`INCLUDED BY
`
`~Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`D Answer
`
`D Cross Bill
`
`D Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`I U.S. 8,603,514
`
`12/10/2013
`
`MonoSol RX, LLC
`
`2
`
`3
`
`4
`
`5
`
`I DECISION/JUDGEMENT
`
`In the above-entitled case, the following decision has been rendered or judgement issued:
`
`!'BY) DEPIITY CLERK
`
`Copy 1-Upon initiation of action, mail this copy to Director Copy 3-Upon termination of action, mail this copy to Director
`Copy 2-Upon filing document adding patcnt(s), mail this copy to Director Copy 4-Case file copy
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Case 1:13-cv-02003-RGA Document 24 Filed 01124114 Page 1 of 1 PageiD #: 322
`
`AO 120 (Rev 08/10)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S. C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`DELAWARE
`on the following
`filed in the U.S. District Court
`0 Trademarks or
`( 0 the patent action involves 35 U.S.C. § 292.):
`
`[J?Patents.
`
`DOCKET NO.
`13-cv-2003-RGA
`PLAINTIFF
`Reckitt Benckiser Pharmaceuticals, Inc., RB
`Pharmaceuticals Limited, and MonoSol RX, LLC
`
`DATE FILED
`12/6/2013
`
`U.S. DISTRICT COURT
`
`DELAWARE
`
`DEFENDANT
`Alvogen Pine Brook, Inc.
`
`PATENTOR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`1 8,475,832
`
`2 8,017,150
`
`7/2/2013
`
`9/13/2011
`
`RB Pharmaceuticals Limited
`
`MonoSol RX, LLC
`
`3
`
`4
`
`5
`
`In the above--entitled case, the following patent(s)/ trademark(s) have been included:
`
`DATE INfh~~~ 4
`
`PATENTOR
`TRADEMARK NO.
`
`INCLUDED BY
`
`[!j" Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`0 Answer
`
`0 Cross Bill
`
`0 Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`1 8,603,514
`
`12/10/2013
`
`MonoSol RX, LLC
`
`2
`
`3
`
`4
`
`5
`
`In the above--entitled case, the following decision has been rendered or judgement issued:
`
`DECISION/JUDGEMENT
`
`I (BY) DEPUTY CLERK
`
`Copy 1-Upon initiation of action, mail this copy to Director Copy 3--Upon termination of action, mail this copy to Director
`Copy 2-Upon filing document adding patent(s), mail this copy to Director Copy 4--Case file copy
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Case 1:13-cv-02003-UNA Document 4 Filed 12/06/13 Page 1 of 1 PageiD #: 100
`
`AO 120 (Rev. 08/JQ)
`
`TO:
`
`Mail Stop 8
`Director oftbe U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`Tn Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`DELAWARE
`on the following
`filed in the U.S. District Court
`( 0 the patent action involves 35 U.S.C. § 292.):
`0 Trademarks or
`
`[i?Patents.
`
`DOCKET NO.
`
`DATE FILED
`12/6/2013
`
`U.S. DISTRICT COURf
`
`DELAWARE
`
`PLAINTIFF
`Reckitt Benckiser Pharmaceuticals, Inc., RB
`Pharmaceuticals Limited and MonoSol RX, LLC
`
`DEFENDANT
`Alvogen Pine Brook, Inc. and Alvogen Group, Inc.
`
`PATENTOR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`I 8,475,832
`
`2 8,017,150
`
`7/2/2013
`
`9/13/2011
`
`RB Pharmaceuticals Limited
`
`MonoSol RX, LLC
`
`3
`
`4
`
`5
`
`In the above-entitled case, the following patent(s)/ trademark(s) have been included:
`
`DATE INCLUDED
`
`PATENTOR
`TRADEMARK NO.
`
`INCLUDED BY
`
`0 Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`0 Answer
`
`0 Cross Bill
`
`D Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`I
`
`2
`
`3
`
`4
`
`5
`
`In the above-entitled case, the following decision has been rendered or judgement issued:
`
`DECISION/JUDGEMENT
`
`I (BY) DEPUlY CJ ERK
`
`Copy 1-Upon initiation of action, mail this copy to Director Copy 3--Upon termination of action, mail this copy to Director
`Copy 2-Upon filing document adding patent(s), mail this copy to Director Copy 4-Case file copy
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Case 1:13-cv-01674-UNA Document 4 Filed 10/08/13 Page 1 of 1 PageiD #: 101
`
`AO 120 (Rev. 08/10)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`of Delaware
`filed in the U.S. District Court
`on the following
`D Trademarks or
`( D the patent action involves 35 U.S.C. § 292.):
`
`[i?Patents.
`
`DOCKET NO.
`
`DATE FILED
`10/8/2013
`
`U.S. DISTRICT COURT
`
`of Delaware
`
`DEFENDANT
`PLAINTIFF
`RECKITT BENCKISER PHARMACEUTICALS, INC., RB WATSON LABORATORIES, INC. and ACTAVIS, INC.
`PHARMACEUTICALS LIMITED and MONOSOL RX, LLC,
`
`PATENTOR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`I U.S. 8,475,832
`
`2 U.S. 8,017,150
`
`7/2/2013
`
`9/13/2011
`
`RB Pharmaceuticals Limited
`
`MonoSol Rx, LLC
`
`3
`
`4
`
`5
`
`In the above-entitled case, the following patent(s)/ trademark(s) have been included:
`
`DATE INCLUDED
`
`INCLUDED BY
`
`PATENTOR
`TRADEMARK NO.
`
`D Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`D Answer
`
`D Cross Bill
`
`0 Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`I
`
`2
`
`3
`
`4
`
`5
`
`In the above-entitled case, the following decision has been rendered or judgement issued:
`
`DECISION/JUDGEMENT
`
`I (BY) DEPUTY CLERK
`
`Copy 1-Upon initiation of action, mail this copy to Director Copy 3---Upon termination of action, mail this copy to Director
`Copy 2-Upon filing document adding patent(s), mail this copy to Director Copy 4-Case file copy
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Case 1:13-cv-01461-UNA Document 4 Filed 08/20/13 Page 1 of 1 PageiD #: 103
`
`A0120(Rev 08/10)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`of Delaware
`filed in the U.S. District Court
`on the following
`0 Trademarks or MPatents.
`( 0 the patent action involves 35 U.S.C. § 292.):
`
`DOCKET NO.
`
`DATE FILED
`8/20/2013
`
`U.S. DISTRICT COURT
`
`of Delaware
`
`DEFENDANT
`PLAINTIFF
`PAR PHARMACEUTICAL, INC., INTELGENX
`RECKITT BENCKISER PHARMACEUTICALS, INC., RB
`PHARMACEUTICALS LIMITED and MONOSOL RX, LLC, TECHNOLOGIES CORP., and L TS LOHMANN THERAPY
`SYSTEMS CORP.
`
`PATENT OR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`I U.S. 8,475,832
`
`2 U.S. 8,017,150
`
`7/2/2013
`
`9/13/2011
`
`RB Pharmaceuticals Limited
`
`MonoSol Rx, LLC
`
`3
`
`4
`
`5
`
`In the above--entitled case. the following patent(s)/trademark(s) have been included:
`
`DATI INCLUDED
`
`PATENTOR
`TRADEMARK NO.
`
`INCLUDED BY
`
`0 Amendment
`DATE OF PATENT
`OR TRADEMARK
`
`0 Answer
`
`0 Cross Bill
`
`D Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`I
`
`2
`
`3
`
`4
`
`5
`
`In the above--entitled case. the following decision has been rendered or judgement issued:
`
`DECISION/JUDGEMENT
`
`l(llY) DEPUTY CLERK
`
`Copy 1-llpon initiation of action, mail this copy to Director Copy 3--llpon termination of action, mail this copy to Director
`Copy 2-llpon filing document adding patent(s), mail this copy to Director Copy 4-Case file copy
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`UNITED STATES pATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www .uspto.gov
`
`APPLICATION NO.
`
`12/107,389
`
`ISSUE DATE
`
`09/13/2011
`
`PATENT NO.
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`8017150
`
`1199-26 DIV
`
`9641
`
`23869
`7590
`08/24/2011
`HOFFMANN & BARON, LLP
`6900 JERICHO TURNPIKE
`SYOSSET, NY 11791
`
`The projected patent number and issue date are specified above.
`
`ISSUE NOTIFICATION
`
`Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
`(application filed on or after May 29, 2000)
`
`The Patent Term Adjustment is 364 day(s). Any patent to issue from the above-identified application will
`include an indication of the adjustment on the front page.
`
`If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that
`determines Patent Term Adjustment is the filing date of the most recent CPA.
`
`Applicant will be able to obtain more detailed information by accessing the Patent Application Information
`Retrieval (PAIR) WEB site (http://pair.uspto.gov).
`
`Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the
`Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee
`payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management
`(ODM) at (571)-272-4200.
`
`APPLICANT(s) (Please see PAIR WEB site http://pair.uspto.gov for additional applicants):
`
`Robert K. Yang, Flushing, NY;
`Richard C. Fuisz, McLean, VA;
`Gary L. Myers, Kingsport, TN;
`Joseph M. Fuisz, Washington, DC;
`
`IR103 (Rev. 10/09)
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`Receipt date: 07/29/2010
`PTO/SB/08a (01-10)
`Doc code: IDS
`Approved for use through 07/31/2012. OMB 0651-0031
`Doc description: Information Disclosure Statement (IDS) Filed
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`12107389- GAU: 1617
`
`IN FORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`12107389
`
`2008-04-22
`
`First Named Inventor
`
`I Robert K. Yang
`
`Art Unit
`
`1611
`
`Examiner Name
`
`I Gina C. Yu
`
`Attorney Docket Number
`
`1199-26 DIV
`
`Examiner Cite
`Initial*
`No
`
`Patent Number
`
`Kind
`Code1
`
`Issue Date
`
`Name of Patentee or Applicant
`of cited Document
`
`Pages,Columns,Lines where
`Relevant Passages or Relevant
`Figures Appear
`
`U.S.PATENTS
`
`I Remove I
`
`1
`
`4880416
`
`1989-11-14
`
`Horiuchi et al
`
`( hange(s) apf lied
`
`t document,
`/fv\.C.J:j
`7 28/2011
`
`2
`
`5800832
`
`1998
`~-09-01
`
`Tapolsky et al
`
`3
`
`6800329
`
`82
`
`2004-10-05
`
`Horstmann et al
`
`4
`
`7579019
`
`82
`
`2009-08-25
`
`Tapolsky et al
`
`If you wish to add additional U.S. Patent citation information please click the Add button.
`
`U.S.PATENT APPLICATION PUBLICATIONS
`
`I Add I
`I Remove I
`
`Examiner
`Initial*
`
`Cite No
`
`Publication
`Number
`
`Kind Publication
`Code1 Date
`
`Name of Patentee or Applicant
`of cited Document
`
`Pages,Columns,Lines where
`Relevant Passages or Relevant
`Figures Appear
`
`1
`
`2
`
`20040191302
`
`A1
`
`2004-09-30
`
`Davidson
`
`20050048102
`
`A1
`
`2005-03-03
`
`Tapolsky et al
`
`EFS Web 2.1.17
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.Y./
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`[0117]
`
`1be actives employed in the present invention may be incorporated into the film
`
`compositions of the present invention in a controlled release form. For example, particles of
`
`drug may be coated with polymers such as ethyl cellulose or polymethacrylate, commercially
`
`available under brand names such as Aquacoat ECD and Eudragit E-1 00, respectively. Solutions
`
`of drug may also be absorbed on such polymer materials and incorporated into the inventive film
`compositions. Other components such as fats and waxes, as well as sweeteners and/or flavors
`
`may also be employed in such controlled release compositions.
`
`[01 1 8]
`
`The actives may be taste-masked prior to incorporation into the film composition,
`
`as set forth in co-pending PCT application titled, Uniform Films For Rapid Dissolve Dosage
`
`Fom1 Incorporating Taste-Masking Compositions, (based on U.S. Provisional Application No.
`60/+1+,276
`Express Mail Label No.: EU552991605 US of the same title, filed September 27, 2003, etten•~)
`_
`Change(s) applied
`~~~~~~~~) the entire subject matter of which is incorporated by reference herein.
`to document,
`/J.Lo/
`8/15/2011
`
`Actives
`
`[0119]
`
`When an active is introduced to the film, the amount of active per unit area is
`
`determined by the uniform distribution of the film. For example, when the films are cut into
`
`individual dosage forms, the amount of the active in the dosage form can be known with a great
`
`deal of accuracy. This is achieved because the amount of the active in a given area is
`
`substantially identical to the amount of active in an area of the same dimensions in another part
`
`of the film. The accuracy in dosage is particularly advantageous when the active is a
`
`medicament, i.e. a drug.
`
`[0120]
`
`The active components that may be incorporated into the films of the present
`
`invention include, without limitation pharmaceutical and cosmetic actives, drugs, medicaments,
`
`proteins, antigens or allergens such as ragweed pollen, spores, microorganisms, seeds,
`
`mouthwash components, flavors, fragrances, enzymes, preservatives, sweetening agents,
`
`colorants, spices, vitamins and combinations thereof.
`
`(0121)
`
`A wide variety of medicaments, bioactive active substances and pharmaceutical
`
`compositions may be included in the dosage forms of the present invention. Examples of useful
`
`31
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`12107389 -~a"a~fb~)1
`Doc code :IDS
`Approved for use through 0813tl2008. OMB 065t-003t
`Doc description: Information Disclosure Statement (IDS) Filed
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`IN FORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`12107389
`
`2008-04-22
`
`First Named Inventor
`
`I Robert K. Yang
`
`Art Unit
`
`1794
`
`Examiner Name
`
`I
`Attorney Docket Number
`
`1199-26 DIV
`
`Examiner Cite
`Initial*
`No
`
`Patent Number
`
`Kind
`Cadet
`
`Issue Date
`
`Name of Patentee or Applicant
`of cited Document
`
`Pages,Columns,Lines where
`Relevant Passages or Relevant
`Figures Appear
`
`U.S.PATENTS
`
`I Remove I
`
`1
`
`6264981
`
`81
`
`2001-07-24
`
`Zhang et al.
`
`If you wish to add additional U.S. Patent citation information please click the Add button.
`
`U.S.PATENT APPLICATION PUBLICATIONS
`
`I Add
`I
`I Remove I
`
`Examiner Cite
`Initial*
`No
`
`Publication Number
`
`Kind Publication
`Cadet Date
`
`Name of Patentee or Applicant
`of cited Document
`
`Pages,Columns,Lines where
`Relevant Passages or Relevant
`Figures Appear
`
`1
`
`20030069263
`
`A1
`
`2003-04-10
`
`Breder et al.
`
`2
`
`20070148097
`
`A1
`
`2007-06-28
`
`Finn et al.
`
`If you wish to add additional U.S. Published Application citation information please click the Add button .I Add
`I
`IRemovel
`FOREIGN PATENT DOCUMENTS
`
`Examiner Cite Foreign Document
`No Number3
`Initial*
`
`Country
`Code2 i
`
`Kind Publication
`Code4 Date
`
`Name of Patentee or
`Applicant of cited
`Document
`
`Pages,Columns,Lines
`where Relevant
`Passages or Relevant
`Figures Appear
`
`T5
`
`1
`
`D
`
`If you wish to add additional Foreign Patent Document citation information please click the Add button I Add
`I
`IRemovel
`
`NON-PATENT LITERATURE DOCUMENTS
`
`EFS Web 2.t.4
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.Y./
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`IN FORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`Filing Date
`
`12107389
`
`2008-04-22
`
`First Named Inventor
`
`I Robert K. Yang
`
`Art Unit
`
`1794
`
`Examiner Name
`
`I
`Attorney Docket Number
`
`1199-26 DIV
`
`12107389- GAU: 1611
`
`Examiner Cite
`Initials* No
`
`Include name of the author (in CAPITAL LETTERS}, title of the article (when appropriate}, title of the item
`(book, magazine, journal, serial, symposium, catalog, etc}, date, pages(s), volume-issue number(s),
`publisher, city and/or country where published.
`
`T5
`
`1
`
`D
`
`If you wish to add additional non-patent literature document citation information please click the Add button I Add I
`EXAMINER SIGNATURE
`
`Examiner Signature I
`
`/Gina Yu/
`
`I
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a
`citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
`
`I Date Considered
`
`04/08/2010
`
`1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WI PO
`Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
`4 Kind of document by the appropriate symbols as indicated on the document under WI PO Standard ST.16 if possible. 5 Applicant is to place a check mark here i
`English language translation is attached.
`
`EFS Web 2.1.4
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.Y./
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`UNITED STA 1ES p A 1ENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`APPLICATION NO.
`
`FILING DATE
`
`FIRST NAMED INVENTOR
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`121107,389
`
`04/22/2008
`
`Robert K. Yang
`
`1199-26 DIV
`
`9641
`
`23869
`7590
`07/27/2011
`HOFFMANN & BARON, LLP
`6900 JERICHO TURNPIKE
`SYOSSET, NY 11791
`
`EXAMINER
`
`YU,GINAC
`
`ART UNIT
`
`PAPER NUMBER
`
`1617
`
`MAIL DATE
`
`DELIVERY MODE
`
`07/27/2011
`
`PAPER
`
`Please find below and/or attached an Office communication concerning this application or proceeding.
`
`The time period for reply, if any, is set in the attached communication.
`
`PTOL-90A (Rev. 04/07)
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`UNITED STATES DEPARTMENT OF COMMERCE
`U.S. Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`
`APPLICATION NO./
`CONTROL NO.
`12/107,389
`
`FILING DATE
`
`22 April, 2008
`
`FIRST NAMED INVENTOR I
`PATENT IN REEXAMINATION
`YANGETAL.
`
`A HORNEY DOCKET NO.
`
`1199-26 DIV
`
`HOFFMANN & BARON, LLP
`6900 JERICHO TURNPIKE
`SYOSSET, NY 11791
`
`EXAMINER
`
`GINA C. YU
`
`ART UNIT
`
`PAPER
`
`1617
`
`20110706
`
`DATE MAILED:
`
`Please find below and/or attached an Office communication concerning this application or
`proceeding.
`
`Commissioner for Patents
`
`/GINA C. YU/
`Primary Examiner, Art Unit 1617
`
`PT0-90C (Rev.04-03)
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`UNITED STATES DEPARTMENT OF COMMERCE
`United Stoteo Patent and Trademark Office
`Addren: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria. Vuginio 223 I 3-1450
`www.UiptO.gov
`
`CONFIRMATION NO. 9641
`
`CLASS
`424
`
`GROUP ART UNIT
`1617
`
`ATIORNEY
`DOCKET NO.
`1199-26 DIV
`
`lllllllllllllllllllln Ill~ lln!IU 11111111111111111111111111111111
`
`Bib Data Sheet
`
`SERIAL NUMBER
`12/107,389
`
`FILING OR 371 (c)
`DATE
`04/22/2008
`RULE
`
`~PPLICANTS
`Robert K. Yang, Flushing, NY;
`Richard C. Fuisz, Mclean, VA;
`Gary L. Myers, Kingsport, TN;
`Joseph M. Fuisz, Washington, DC;
`
`I*• CONTINUING DATA *************************
`This application is a DIV of 10/856,176 05/28/2004 PAT 7,666,337 which claims benefit of 60/473,902
`05/28/2003
`and is a CIP of PCT/US2002/032575 10/11/2002
`and is a CIP of PCT/U$02/32594 10/11/2002
`which claims benefit of 60/414,276 09/27/2002
`and said 1 0/856,176 05/28/2004
`is a CIP of PCT/U$02/32542 10/11/2002
`which claims benefit of 60/371,940 04/11/2002
`
`I** FOREIGN APPLICATIONS ********************
`
`IF REQUIRED, FOREIGN FILING LICENSE GRANTED
`** 05/06/2008
`Foreign Priority claimed
`
`~5 USC 119 (a-d) conditions
`met
`!verified and
`~cknowledged
`!ADDRESS
`l23869
`~ITLE
`
`Examiner's Signature
`
`Initials
`
`CJ yes CJ no
`CJ yes CJ no CJ Met after
`Allowance
`
`STATE OR
`COUNTRY
`NY
`
`SHEETS
`DRAWING
`26
`
`TOTAL
`CLAIMS
`18
`
`INDEPENDENT
`CLAIMS
`2
`
`POLYETHYLENE OXIDE-BASED FILMS AND DRUG DELIVERY SYSTEMS MADE THEREFROM
`
`FILING FEE FEES: Authority has been given in Paper
`RECEIVED No.
`to charge/credit DEPOSIT ACCOUNT
`735
`No.
`for following:
`
`ICJ All Fees
`ICJ 1.16 Fees (Filing)
`CJ 1.17 Fees ( Processing Ext. of
`time)
`ICJ 1.18 Fees (Issue)
`ICJ Other
`ICJ Credit
`
`I
`I
`I
`
`TEVA EXHIBIT 1002
`TEVA PHARMACEUTICALS USA, INC. V. MONOSOL RX, LLC
`
`

`
`PART B - FEE(S) TRANSMITTAL
`
`Complete and send this form, together with applicable fee(s), to: Mail
`
`or Fax
`
`Mail Stop ISSUE FEE
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`(571) 273-2885 =
`
`lNS l RUCTIONS: This fonr; should be used for transmitting the ISSUE FEE and PUBLlCATION l~Eb (if required). Blocks l through 5 shouJd be completed where
`appropriate. ~All further cviTespondence inclwJ~ng the Patenlt ad vance orders and not~ficativn of rnairnenoJ:lc,e fees 'Nill be mailed to the current corre,sponde~1c~ _add.l'ess as
`indicated unless cor!ected below~ or directed otherw]se in Block j, by (a} speci(ving ,1 ne1v correspondence address; and/or (b) indicating a separate ~>FEE ADDRESS 1
`, for
`rnaintenm1ce fee notifications"
`C1JRRENT CORRESPONDENCE ADDRESS (Note: Use 81ock 1 fm :-my change of address)
`
`Note:. A certit1cate of _n1aihng can onJy be used for domest]c n1aibngs of the
`Fee(sJ Transrnittal. Th1s certiilcate cannot be used for any other acc.o1npanying
`papers. Each addi~ional P;1per,_such as an assignment or formal drawing, must
`have 1ts own certlllC!He ot rna111ng or t.l'ansllllSS10rL
`
`HOFFMANN & BARON, LLP
`6900 JERICHO TURNPIKE
`SYOSSET, NY 11791
`
`Certificate of ,'Halling or Transmission
`I hereby certify that this Fee(s) Transmittal is being deposited wiG'J L'Je United
`States Postal Service \Vith suffic~.ent postage for first class rn3~l1n an envelope
`addressed to the Mail Stop ISSUE FEE address above, or being facsim1le
`rn:lnsrnitted to the USPT'O (571) 273-2885~ on tlie date indic:Jted belo;,v.
`
`Debra Chambliss
`
`July 22, 2011
`
`'Depc-:itor·~ naroe)
`
`(Slgr,ature)
`
`(Dote)
`
`I
`
`APPLICATION NO.
`
`12/107,389
`TlTLE OF lNVENTlON:
`
`I
`
`HUNG DATE
`
`04/22/2008
`
`I
`
`FL.'ZST NAJV!ED INVENTOR
`
`CONFIRMATION NO.
`
`Robert K. Yang
`
`1199-26 DIV
`
`9641
`
`APl'LN.TYf'E
`
`SMALL ENTITY
`
`lSSUE l0EE
`
`PUBL!CATlON fEE
`
`TOTAL FEE(S) DUE
`
`DATE DUE
`
`non provisional
`
`YES
`
`$755
`
`$300
`
`$1055
`
`08/08/2011
`
`EXAMINER
`
`ARTUNfT
`
`CLASS-SUBCLASS
`
`l. (J)ange of correspondence addfess or ind~cat~on of 1'Fee AddressH (37
`CFR !.363).
`0 C'hange of corre~pondence add;1-:ss (or Change of Correspondence
`Address fonn PTO/sB/!22) attached.
`0 ''Fee _A._dtlress 1
`' indic.ation (or Hfee Ackh·ess'' Indic.ation fonn
`PTO/S.B/47; Rev 03-02 or 1nore recent) attached. llse of a Custon1cr
`Number i5 req t.~ired.
`
`2. For printing on the patent front page. 1ist
`{l) L'Je names of up to 3 registered patent attorneys
`or agents OH"J alternativcJy)
`{2) the narne of a single firm (having as a :!Jlember a
`registered attorney or agent) and the names of up to
`2 registered patent atto-:_ueys or agents. If no name is
`listedt no name "vill be printed.
`
`1 Hoffmann & Baron, LLP
`
`2
`
`3
`
`3" ASSIGNEE NA1\iE AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (prim or type)
`PLE_ASE NOTE: Unless :Jn assignee is 1dentified bdo;,v) no assignee data wiU appear on tbe patent lf an assig;)ee is ident~tled bd_o;,vJ r])e docurrJent has been filed f't1r
`recordation as set forth in 37 CFR 3.11. Completion ofthis form is NOT a substitute for Jiling an assignment.
`
`{A) NAME OF ASSIGNEE
`MonoSol Rx, LLC
`
`{B) RESIDENCE: (ClTY 3nd STATE OR COUNTHY)
`Portage, IN
`
`Please check the appropriate assignee category or categories (vvill not be printed on the patent): 0 Individual ~Corporation or other private group entity 0 G-overnment
`4b. Payment ofh:e(s):
`4a. The following fee{ s) are enclosed:
`0 A check in the ammmt of the fee{s) is enclosed.
`eJ Issue Fee
`~ Pubhc:Jtion Fee (No srnaH entity djscount pennitted)
`[] Pay!nent by credit card. Fonn PT0-2038 is attached.
`tJ Tbe Director is hereby authorized bv charge the requ]red fee(s), or credit any over:pay-:_nent. to
`~~ Advance Order- If of Copies _
`082461
`.
`Deposit Accmmt Number
`
`5. Change: in Entity Status (frcnn stat1:s indicated above)
`eJ b. Applic~mt is no longer claiming STv